Format

Send to

Choose Destination
Urology. 2015 May;85(5):976-986. doi: 10.1016/j.urology.2014.12.029. Epub 2015 Feb 20.

Current and Emerging Immunotherapies for Castration-resistant Prostate Cancer.

Author information

1
Division of Urology, Department of Surgery, Centre Hospitalier de I'Université de Montréal, Montréal, Quebec, Canada. Electronic address: fred.saad@umontreal.ca.
2
Department of Urology, Charité Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany.

Abstract

Despite advances in castration-resistant prostate cancer (CRPC) treatment, therapies that provide long-term survival are still needed. In 2010, sipuleucel-T was approved for CRPC on the basis of improved overall survival. Recently, new immunotherapeutic approaches have emerged with perhaps the most exciting being immune-checkpoint inhibition. Here, we provide an overview of immunotherapies for CRPC, with a focus on immune-checkpoint inhibition with ipilimumab. We consider how experience with ipilimumab in melanoma might inform future use in CRPC and describe ongoing phase 3 trials. Finally, we discuss the potential for improved antitumor activity when ipilimumab is combined with hormonal or bone-targeted agents.

PMID:
25709051
DOI:
10.1016/j.urology.2014.12.029
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center